Q Bio, the company building technology for the Physical of the Future, today unveiled its “digital twin” platform, the first to capture and monitor comprehensive baseline patient health in a scalable virtual model. In addition, the company announced an investment from Kaiser Foundation Hospitals that brings its total capital to more than $80 million, including Series B funding led by Andreessen Horowitz, to develop and expand access to its proprietary platform and breakthrough whole-body scanning technologies that enable data-driven, proactive, and more affordable preventive care for all.
The company’s platform, called Q Bio Gemini, automatically reflects an individual’s most accurate physiological state in the form of a digital twin, highlighting the most important changes in a person’s physiology in a comprehensive summary that can be securely shared with physicians and specialists all over the world.
Powering the Gemini platform is the Q Bio Mark I self-driving, whole-body scanner – the fastest, most accessible scanner developed, and the first scanner optimized for proactive care. The Mark I scanner collects information based on current health and personal risks, adapting in real time to changes in an individual’s anatomy and biochemistry that are weighted by lifestyle, medical history, and genetic risk factors. Capable of scanning the whole body in 15 minutes or less without radiation, breath holds, or claustrophobia, the scanner provides individuals with maximum comfort in an open space, including the option to stand, sit, or lie down.
The Mark I offers faster and more precise medical scanning without the use of artificial intelligence or machine learning, avoiding issues with bias and “hallucinations.” The company’s technology, which is based on advanced computational biophysics, has been shown to be at least 10x faster than conventional MRI scans without the loss of diagnostic quality, and allows for the construction of dramatically cheaper hardware, with rapid deployment and reduced operational costs.
“Until now, no existing technology has been able to develop a digital twin in a cost-effective way that combines an individual’s genetics, chemistry, anatomy, lifestyle, and medical history over time, with integrated tools that make it easy to correlate between quantitative changes and an individual’s risk factors,” said Jeffrey Kaditz, founder and CEO of Q Bio. “Our ability to digitize the human body is advancing on a price performance basis faster than Moore’s Law, except at the anatomical scale. The Mark I is the missing tool for delivering this virtual model today, enabling not only immediate clinical uses like stratifying risk in populations in order to route care most effectively, but also leading to a much deeper understanding of the progression of many kinds of disease, and ultimately personalized health forecasts at scale.”
“With the unveiling of its digital twin platform, Q Bio continues to make breakthroughs in clinical precision, reproducibility, and speed that place its non-invasive whole-body scanner far ahead of standard imaging techniques,” said Vijay Pande, General Partner at Andreessen Horowitz. “The company’s approach offers the most comprehensive ability to measure and monitor the health of entire populations to help establish a new era of proactive care.”
To learn more about the Q Bio Gemini platform and Mark I scanner, clinical partnership opportunities, and careers, please visit q.bio.
About Q Bio
Founded in 2015, Q Bio develops breakthrough technology to measure more, faster and cheaper, about the human body to enable proactive primary care for all. The company has built the first clinical digital twin platform, Q Bio Gemini, powered by its proprietary Mark I whole-body scanner – the fastest, most accessible scanner developed for routine clinical use. Investors include Andreessen Horowitz, Kaiser Foundation Hospitals, Khosla Ventures, Founders Fund, Beast Ventures, Thirty Five Ventures, XCap, Terry Crews, Sea Lane Ventures, SciFi VC and others. To learn more, visit q.bio.